NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT01618136 2023-06-18An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsEisai Inc.Phase 1/2 Completed41 enrolled
NCT00003230 2012-05-15Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous LeukemiaSwiss Cancer InstitutePhase 1/2 Completed33 enrolled
NCT00004105 2011-03-28Combination Chemotherapy in Treating Patients With Advanced CancerNYU Langone HealthPhase 1/2 Completed